Results 151 to 160 of about 23,951 (282)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier   +7 more
wiley   +1 more source

AEG‐AESPANC‐OPGE‐SIED‐SPG Ibero‐Latin American Guidelines on Acute Pancreatitis (iLATAM‐AP)

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Introduction Acute pancreatitis (AP) is a major cause of gastrointestinal hospitalizations worldwide. Although typically self‐limiting, up to one‐third of cases develop complications associated with increased morbidity and mortality. Despite recent advances that have improved outcomes, clinical heterogeneity necessitates updated, evidence ...
Karina Cárdenas‐Jaén   +44 more
wiley   +1 more source

Decreased renal function predicts severe cytokine release syndrome after CAR‐T‐cell therapy for large B‐cell lymphoma

open access: yesBritish Journal of Haematology, Volume 208, Issue 6, Page 2124-2133, June 2026.
Summary Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL), and robust pre‐infusion predictors are needed for risk‐adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR‐T‐cell therapy between 2019 ...
Yasuyuki Arai   +21 more
wiley   +1 more source

Febrile neutropenia adversely affects chemomobilization outcomes in patients with multiple myeloma and increases risk for post-transplant infection in those with lymphoma: real-world multicenter data. [PDF]

open access: yesBlood Sci
Qian H   +17 more
europepmc   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta   +12 more
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso   +18 more
wiley   +1 more source

Transfusion medicine, apheresis, and hemostasis : review questions and case studies /

open access: yes
Includes index.Vendor-supplied metadata.Cover -- Title page -- Copyright page -- Dedication -- Contents -- Contributors -- About the Editors -- Preface -- Acknowledgment -- Laboratory Reference Ranges -- Chapter 1 -- Pretest -- Answers and brief ...
Pham, Huy P.,editor.   +1 more
core  

Home - About - Disclaimer - Privacy